Q32 Bio (QTTB) CEO receives 132,000-share stock unit grant

Rhea-AI Filing Summary

Morrison Jodie Pope reported acquisition or exercise transactions in this Form 4 filing.

Q32 Bio Inc. reported that CEO and director Jodie Pope Morrison received a grant of 132,000 shares of Common Stock on February 24, 2026 at a price of $0.0000 per share. Following this award, her directly held Common Stock position is 221,104 shares.

The award is structured as restricted stock units (RSUs). The RSUs vest in four equal 25% installments: 6, 12, 24, and 36 months from the February 24, 2026 grant date. Each RSU represents a contingent right to receive one share of Q32 Bio common stock as it vests.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Morrison Jodie Pope

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	132,000	$0.00	--

Holdings After Transaction: Common Stock — 221,104 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrison Jodie Pope

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A(1)		132,000	A	$0	221,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2026 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.

	/s/ Eric Bell, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Q32 Bio (QTTB) disclose for its CEO?

Q32 Bio disclosed that CEO and director Jodie Pope Morrison received an award of 132,000 shares of Common Stock on February 24, 2026. The grant was recorded at $0.0000 per share as a compensation-related acquisition, not an open-market purchase.

How many Q32 Bio (QTTB) shares does the CEO hold after this Form 4?

After this transaction, CEO Jodie Pope Morrison directly holds 221,104 shares of Q32 Bio Common Stock. This figure reflects her position immediately following the 132,000-share compensation grant reported in the Form 4 filing with the SEC.

How do the Q32 Bio (QTTB) CEO’s RSUs from this grant vest?

The restricted stock units tied to this grant vest in four equal 25% installments. Vesting occurs 6, 12, 24, and 36 months from the February 24, 2026 grant date. Each vested RSU delivers one share of Q32 Bio common stock.

Is the Q32 Bio (QTTB) CEO’s 132,000-share award an open-market stock purchase?

No, the 132,000-share transaction is classified as a grant or award acquisition, not an open-market purchase. It represents compensation in the form of restricted stock units rather than the CEO buying shares on the public market.

What does each RSU in the Q32 Bio (QTTB) CEO grant represent?

Each restricted stock unit in this award represents a contingent right to receive one share of Q32 Bio common stock. Shares are actually issued only as the RSUs vest over the four scheduled installments after the February 24, 2026 grant date.